Teachers Retirement System of The State of Kentucky Trims Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Teachers Retirement System of The State of Kentucky lessened its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 37.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 255,128 shares of the medical equipment provider's stock after selling 150,603 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Boston Scientific were worth $21,380,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of BSX. Triad Wealth Partners LLC bought a new stake in Boston Scientific during the 2nd quarter worth $26,000. Values First Advisors Inc. bought a new stake in shares of Boston Scientific during the third quarter worth about $28,000. Dunhill Financial LLC increased its stake in shares of Boston Scientific by 86.4% in the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 152 shares during the period. Andra AP fonden acquired a new position in shares of Boston Scientific in the second quarter valued at approximately $29,000. Finally, E Fund Management Hong Kong Co. Ltd. bought a new position in Boston Scientific in the 3rd quarter valued at approximately $30,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Activity

In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of the business's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the transaction, the chief executive officer now directly owns 1,572,096 shares in the company, valued at $133,046,484.48. The trade was a 9.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.86, for a total transaction of $585,594.38. Following the sale, the executive vice president now owns 34,748 shares of the company's stock, valued at approximately $2,913,967.28. The trade was a 16.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 328,157 shares of company stock worth $27,957,676 over the last quarter. Insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BSX shares. BTIG Research boosted their target price on shares of Boston Scientific from $84.00 to $93.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Canaccord Genuity Group boosted their price objective on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a "buy" rating in a research note on Monday. Evercore ISI raised their target price on Boston Scientific from $82.00 to $90.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Wells Fargo & Company upped their price target on Boston Scientific from $98.00 to $100.00 and gave the company an "overweight" rating in a research report on Wednesday. Finally, Citigroup increased their price target on Boston Scientific from $98.00 to $107.00 and gave the company a "buy" rating in a research note on Wednesday. Four research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $94.43.

Boston Scientific Stock Down 0.2 %

Shares of Boston Scientific stock traded down $0.14 during trading hours on Thursday, reaching $90.42. The company's stock had a trading volume of 4,050,797 shares, compared to its average volume of 5,982,173. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. Boston Scientific Co. has a one year low of $54.95 and a one year high of $91.93. The company has a market capitalization of $133.26 billion, a P/E ratio of 74.81, a P/E/G ratio of 2.65 and a beta of 0.80. The stock's fifty day simple moving average is $87.74 and its two-hundred day simple moving average is $81.61.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The firm had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same period in the prior year, the business posted $0.50 earnings per share. The company's quarterly revenue was up 19.3% compared to the same quarter last year. On average, research analysts forecast that Boston Scientific Co. will post 2.46 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.